Cell viability in NRAS-mutant melanoma cells
Cell-based study · melanoma cells with NRAS mutations in exon II (NRAS G12), exon III (NRAS Q61) [1]
Melanoma cells with NRAS mutations were incubated with ML349 at <12.5 μM for 72hrs, with DMSO-treated controls. ML349 did not decrease cell viability at the dosages used.
| Endpoint | Reported result | Reference |
|---|---|---|
| cell viability | Reported result ML348 and ML349 do not decrease cell viability in melanoma cells at dosages used in this study. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- <12.5 μM
- Exposure duration
- incubation 72hrs
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: ML349
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Specific APT-1 and APT-2 inhibitors ML348 and ML349 do not affect cell viability in NRAS mutant melanoma cells (S14); Figure 3 legend (S64, S65)
cell viability: cell viability; comparator: DMSO treated controls — Figure 3 legend (S65)